Featured Download

Case Studies:The SME and CMO Perspectives

Case Studies:The SME and CMO Perspectives

Pharma IQ spoke to Mark Davison, Chief Executive Officer at Blue Sphere Health Ltd to gain insight on his experience working with SME pharma & biotechs for serialisation. Also we spoke to Vetter pharma – a responsible CMO for their insight on how peer CMOs optimise their serialisation strategy.

Serialisation: The South Korean Landscape

Serialisation: The South Korean Landscape

Pharma IQ spoke to Jay Jay Han of Hanmi Pharmaceutical to explore the serialisation landscape in South Korea.

Serialisation: Top Tech Integration Considerations

Serialisation: Top Tech Integration Considerations

Roger Bate from the American Enterprise Institute estimates that global economy is hit by $10 billion in losses due to counterfeit and substandard medicines alone. Undoubtedly, technology stands as a keystone in a controlled track and trace system. In this eBook we look at the key considerations organisations face in finding the right technologies and focus on the strategies for integration to ensure a successful serialisation project.

Serialisation 2015 - What's next for the market?

Serialisation 2015 - What's next for the market?

Pharma IQ spoke to Jean Marc Bobee of Sanofi to find out about what’s next for the market in terms of serialisation.

Traceability In Operation Market Research: Concerns and Priorities

Traceability In Operation Market Research: Concerns and Priorities

Ahead of the traceability in operation forum 2017 Pharma IQ conducted some market research to pinpoint the concerns and priorities of those in the more mature phases of serialisation. Commentary supplied by Pasi Kemppainen, Executive Consultant, Pharma Serialization and Traceability.
The World Beyond Compliance- Serialisation

The World Beyond Compliance- Serialisation

Whilst it is natural for a serialisation program to focus on delivering to the hard legislative deadlines, it can be detrimental if these short term needs limit the project’s long term scope and capabilities. If this is allowed to happen, then reaping the broader future benefits from the serialisation project may prove to be significantly more difficult. Pharma IQ examines the opportunities available when utilising serialisation and traceability systems beyond compliance.